EndoAdvisor Profile Banner
EndocrinologyAdvisor Profile
EndocrinologyAdvisor

@EndoAdvisor

Followers
3K
Following
309
Media
162
Statuses
5K

Endocrinology Advisor provides healthcare professionals with comprehensive information and clinical news on the management of endocrine conditions.

New York, NY
Joined March 2014
Don't wanna be here? Send us removal request.
@EndoAdvisor
EndocrinologyAdvisor
1 day
Quiz Time! Test your knowledge on #nutritional support strategies in #GLP1 use.
0
0
1
@EndoAdvisor
EndocrinologyAdvisor
3 days
One in 14 patients screened for #PrimaryAldosteronism without prior #adrenal imaging had an adrenal mass. @UCalgaryMed @CalDomMed @DalhousieU @UBC @AHS_media .
0
1
1
@EndoAdvisor
EndocrinologyAdvisor
3 days
The prevalence of #MASLD has decreased, whereas the prevalence of #LiverFibrosis and #cirrhosis have increased among US patients with #T2D since 2017. @FernandoBril @KY_HUYNH @UAB_endocrine @UABDiabetes .
0
4
5
@EndoAdvisor
EndocrinologyAdvisor
4 days
From #ADASciSessions: Treatment with #mifepristone vs placebo was associated with improved #glycemia and body weight metrics among patients with #T2D and #hypercortisolism. @IrinaBancos @DoctorEndocrine @endocrine @YHandelsmanMD @StevenKahn11 .
0
0
0
@EndoAdvisor
EndocrinologyAdvisor
4 days
Compared with men, women with #pheochromocytomas and #paragangliomas were less likely to undergo laparoscopic surgery and more likely to achieve #diabetes remission.
0
0
0
@EndoAdvisor
EndocrinologyAdvisor
4 days
Addition of T3 to LT4 therapy may reduce the heightened risks for mortality and #dementia associated with #hypothyroidism. @carvalhalgiulia @Bianco_Lab @mettleson @UFCG_Oficial @UChicagoMed @utmbhealth .
0
2
9
@EndoAdvisor
EndocrinologyAdvisor
5 days
From #ADASciSessions: #CagriSema, compared with placebo, was associated with significant weight loss among adults with #obesity with or without #T2D. @ADA_DiabetesPro @NEJM @carel_leroux @DrSuePedersen .
0
0
0
@EndoAdvisor
EndocrinologyAdvisor
5 days
Successful postoperative #ablation was associated with promising 10-year survival among patients with #FollicularThyroidCarcinoma.
0
0
0
@EndoAdvisor
EndocrinologyAdvisor
5 days
From #ADASciSessions: #Orfoglipron was associated with reductions in #HbA1c and body weight among patients with early-stage #T2D. @ADA_DiabetesPro @NEJM .
0
0
2
@EndoAdvisor
EndocrinologyAdvisor
5 days
Compared with #GLP1RAs, #SGTL2Inhibitors were associated with reduced risks for #osteoarthritis and #JointReplacementSurgery among patients with #T2D.
0
0
1
@EndoAdvisor
EndocrinologyAdvisor
8 days
From #ADASciSessions: Compared with once-daily #degludec, once-weekly insulin efsitora was associated with comparable #GlycemicControl outcomes and improved patient-reported benefits. @ADA_DiabetesPro @Diabetes_ADA @cwysham .
0
1
3
@EndoAdvisor
EndocrinologyAdvisor
8 days
From #ADASciSessions: Compared with placebo, #tirzepatide was associated with a slower decline in #eGFR among patients with #prediabetes and overweight or #obesity. @ADA_DiabetesPro @Diabetes_ADA @KatherineTuttl8 @PBjornstadMD .
3
2
6
@EndoAdvisor
EndocrinologyAdvisor
8 days
From #ADASciSessions: #Semaglutide improved maximum walking distance across #T2D subgroups among patients with symptomatic #PeripheralArteryDisease. @ADA_DiabetesPro @Diabetes_ADA @NedaRasouli2 @SubodhVermaMD @MarcBonaca .
1
1
3
@EndoAdvisor
EndocrinologyAdvisor
9 days
Relative to other second-line therapies, #GLP1RAs were not associated with an increased risk for #ThyroidCancer among patients with #T2D. @FannyBu214 @MichaelEMatheny @wallis_lau @KennethKCMan @JINJINZHOU @TDuarte_Salles @hmkyale @rohan_khera .
0
0
3
@EndoAdvisor
EndocrinologyAdvisor
9 days
Once-weekly #IcoSema vs #InsulinIcodec was associated with significantly improved #GlycemicControl and body weight in inadequately controlled #T2D. @athenatsimikas .
0
0
1
@EndoAdvisor
EndocrinologyAdvisor
10 days
#Pregnancy deferral for at least 3 months was associated with clinically significant #WeightReduction among women with #obesity and #ReproductiveDisorders. @SBSchon_MD @SpizmanJocelyn @umichmedicine @UMichMedSchool .
0
0
0
@EndoAdvisor
EndocrinologyAdvisor
10 days
From #ADASciSessions: Patients with #T2D and a baseline HbA1c greater than 7.0% experienced greater #cardiovascular benefits while using oral #semaglutide. @HeartDocSharon @ADA_DiabetesPro @Diabetes_ADA .
0
1
3
@EndoAdvisor
EndocrinologyAdvisor
10 days
Compared with monotherapy or non-pharmacologic #WeightLoss, a multimodal #AntiObesityMedication regimen elicited more preoperative weight loss in high BMI patients. @_mikekachmar_ @kyle_lapenna @metabolic_knife @PSchauerMD .@PBRCNews @LSUHealthNO .
0
3
6
@EndoAdvisor
EndocrinologyAdvisor
11 days
Among #diabetes progression indicators, #KidneyCancer risk was highest for patients with #ChronicKidneyDisease and diabetes duration of at least 5 years.
0
0
0